A champion of exploring new frontiers as a scientific leader and company builder, with deep expertise in applying machine learning and computational technologies to drug discovery and development.

Rosana co-founded ROME Therapeutics as the first-ever entrepreneur-in-residence at GV (formerly Google Ventures), where she continues to serve as a Life Sciences Fellow. ROME is the industry leader in illuminating the dark genome’s role in human disease and translating these insights into first-in-class therapeutics across a spectrum of diseases. Prior to launching ROME, Rosana was the founding Chief Scientific Officer of Nimbus Therapeutics, where she led the company’s application of advanced computational technologies to the design and development of novel therapeutics. Most notably, Rosana led Nimbus’ discovery efforts for programs targeting acetyl-CoA carboxylase (ACC) and tyrosine kinase 2 (TYK2), which were acquired in blockbuster deals by Gilead and Takeda, respectively.

Rosana is a member of the board of directors of Schrödinger and previously consulted for Third Rock Ventures and Atlas Venture. She sits on the Key Advisory Board for the Blavatnik Fellowship in Life Science Entrepreneurship at Harvard Business School and also serves as an Expert in Residence (XIR) for the Harvard Office of Technology Development.

Recognitions Rosana has received include selection for the Forbes 50 Over 50 Entrepreneurs list (2022), the Endpoints Women in Biopharma list (2019), and the Fierce Pharma Fiercest Women in Life Sciences (2019). She also received a NEVY Award for Rising Star Entrepreneur from the New England Venture Capital Association (2016). Rosana earned her M.D. from Universidade do Estado do Rio de Janeiro in Brazil and her Ph.D. in Molecular and Cellular Biology from Tufts University.